Results of the first Russian study estimating the willingness to pay threshold for one saved quality-adjusted life year in oncology by the conditional assessment method

Abstract

High technologies used to treat patients with cancer, hematologic and rare diseases are always regarded in society as expensive. Modern medicine, particularly oncology and hematology, cannot be imagined today without monoclonal antibodies and genetic engineering. Who must determine the introduction of new and existing procedures into routine practice and how, as well as where are the reference points for those who make decisions in terms of the costs of these treatments? To determine a cost threshold for inclusion or exclusion of new treatments is one of the most important tasks in the light of healthcare reform and drug provision in the Russian Federation. These questions can be answered via studies of the willingness to pay (WTP) threshold. The latter will allow understanding of the country citizens' preference in estimating expenditures for medical products and services. This will in turn enable them to understand more properly the amount of expenses the state has to bear when developing treatment standards and lists of drugs to be freely dispensed.
Within the framework of the study, a questionnaire survey on a random sample of Russia's respondents was conducted to measure WTP for one additional quality adjusted life year, by applying the conditional estimation method and analyzing sociodemographic indicators. According to the results, WTP for one year of life saved with its quality borne in mind was 69,000 rubles or US$2.300, which is much lower, in absolute terms, than those obtained in other countries. Thus, a similar study of WTP for one year of life saved with its quality taken into account showed that WTP was US$41,000 (Japan), 74,000 (Korea), 77,00 (Taiwan), 36,000 (United Kingdom), 47,000 (Australia), and 62,000 (USA). If WTP is compared to the average annual per capita income, Russia approximates that in such countries as the United Kingdom and Japan.

References

  1. Claxton K., Briggs A., Buxton M. J. et al. // Br. Med. J. - 2008. - Vol. 336. - P. 251-254.
  2. George B., Harris A., Mitchell A. // Pharmacoeconomics. - 2001. - Vol. 19. - P. 1103-1109.
  3. Gyrd-Hansen D. // Health Econom. - 2003. - Vol. 12. - P. 1049-1060.
  4. Hirth R. A., Chernew M. E., Miller E. et al. // Medical Decision Making. - 2000. - Vol. 20. - P. 332-342.
  5. Kaplan R. M., Bush J. W. // Health Psychol. - 1982. - Vol. 1. - P. 61-80.
  6. King J. T. Jr., Tsevat J., Lave J. R., Roberts M. S. // Med. Decision Making. - 2005. - Vol. 25. - P. 667-677.
  7. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. // Can. Med. Assoc. J. - 1992. - Vol. 146. - P. 473-481.
  8. Ubel P. A., Hirth R. A., Chernew M. E., Fendrick A. M. // Arch. Intern. Med. - 2003. - Vol. 163. - P. 1637-1640.
  9. Алехина Г. А. // Экономика (Томск. политехн. ун-т). - 2007. - Т. 311, № 6. - С. 119-123.
  10. Бараз В. Р. Корреляционно-регрессионный анализ связи показателей коммерческой деятельности с использованием программы Excel. - Федеральное агентство по образованию ГОУ ВПО Уральский государственный технический университет - УПИ, Екатеринбург, 2005. - С. 102.
  11. Березин И. С. Маркетинговые исследования. Как это делают в России. - М., 2005. - С. 172; 190-198.
  12. Менеджер здравоохранения. - 2010. - № 11. - С. 6.
  13. Figueras J., McKee M., Lessof S. et al. Системы здравоохранения, здоровье и благосостояние: Оценка аргументов в пользу инвестирования в системы здравоохранения. - Всемирная организация здравоохранения, 2008.
  14. Список стран по ВВП (ППС) на душу населения // Википедия. URL: http://ru.wikipedia.org/wiki/%D0%A1%D0% BF%D0%B8%D1%81%D0%BE%D0%BA_%D1%81%D1%8 2%D1%80%D0%B0%D0%BD_%D0%BF%D0%BE_%D0%9 2%D0%92%D0%9F_%28%D0%9F%D0%9F%D0%A1%29_ %D0%BD%D0%B0_%D0%B4%D1%83%D1%88%D1%83_ %D0%BD%D0%B0%D1%81%D0%B5%D0%BB%D0%B5% D0%BD%D0%B8%D1%8F (Дата обращения: 12.09.2010).
  15. www.who.com.

Copyright (c) 2011 Eco-Vector



Свидетельство о регистрации СМИ № 014159 от 23.10.1995 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). 
Свидетельство о регистрации СМИ ЭЛ № ФС 77 - 80673 от 23.03.2021 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies